Cas:54932-68-2 ethyl 2-[cyano(hydroxy)methyl]benzoate manufacturer & supplier

Chemical Name:ethyl 2-[cyano(hydroxy)methyl]benzoate

CAS.NO:54932-68-2

Synonyms:2-(Cyanohydroxymethyl)benzoic acid ethyl ester;Benzoic acid,2-(cyanohydroxymethyl)-,ethyl ester

Molecular Formula:C₁₁H₁₁NO₃

Molecular Weight:205.21000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:70.32000

Exact Mass:205.07400

LogP:1.42028

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-(Cyanohydroxymethyl)benzoic acid ethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzoic acid,2-(cyanohydroxymethyl)-,ethyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzoic acid,2-(cyanohydroxymethyl)-,ethyl ester Use and application,Benzoic acid,2-(cyanohydroxymethyl)-,ethyl ester technical grade,usp/ep/jp grade.

Related News: DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation. ethyl 2-[cyano(hydroxy)methyl]benzoate manufacturer The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. ethyl 2-[cyano(hydroxy)methyl]benzoate supplier Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. ethyl 2-[cyano(hydroxy)methyl]benzoate vendor Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. ethyl 2-[cyano(hydroxy)methyl]benzoate factory Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.